US2018086784A1PendingUtilityA1

Phosphonate analogs of HIV inhibitor compounds

67
Assignee: GILEAD SCIENCES INCPriority: Jul 27, 2004Filed: Jul 6, 2017Published: Mar 29, 2018
Est. expiryJul 27, 2024(expired)· nominal 20-yr term from priority
A61P 31/20A61P 31/18A61P 43/00A61P 31/12A61P 31/00A61P 31/14A61K 31/683A61K 31/341A61K 31/513A61K 31/675A61K 31/662C07F 9/65616A61K 45/06C07H 19/16C07H 19/00C07H 19/20C07F 9/38C07F 9/02A61K 47/50C07F 9/40C07F 9/44A61K 31/7076
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Claims

exact text as granted — not AI-modified
1 .- 104 . (canceled) 
     
     
         105 . A method of treating HIV in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1  is selected from the group consisting of 
 
       
         
           
           
               
               
           
         
       
       and
 R 2  is 
 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         106 . A prophylactic method of reducing a risk of HIV infection in an individual that may be exposed to HIV, comprising administering to the individual a therapeutically effective amount of a compound of the formula 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1  is selected from the group consisting of 
 
       
         
           
           
               
               
           
         
       
       and
 R2 is 
 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.